Could a common diabetes drug also fight gum disease?
NCT ID NCT07182123
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This pilot study will test whether a weekly injection of a GLP-1 receptor agonist (a type 2 diabetes drug) can improve gum health in 30 adults who have both periodontitis and diabetes. Researchers will measure changes in gum pocket depth, bleeding, and tooth mobility. The goal is to gather enough data to plan a larger, more definitive trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GLP-1 receptor agonist (a diabetes drug that may also reduce gum inflammation)
- What this could lead to
- If it works, this could point toward a new way to treat gum disease using existing diabetes medications.
- What could go wrong
- This is a very small pilot study with only 30 people, not yet recruiting. It is designed to gather data for a future trial, not to prove effectiveness. Results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PERIODONTITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Could your bone health decide if a dental implant lasts?
- Blood-Derived clot may regrow bone in gum disease
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes